Deepak Sundriyal1, Lima Arya2, Ruchi Srivastava3, Meenu Walia2, Amit Sehrawat1. 1. Department of Medical Oncology, Hematology, All India Institute of Medical Sciences, Rishikesh, India. 2. Department of Medical Oncology, Max Superspeciality Hospital, New Delhi, India. 3. Department of Pathology, Max Superspeciality Hospital, New Delhi, India.
Abstract
BACKGROUND: Isolated leptomeningeal relapse in a case of cutaneous lymphoma is an uncommon event more so in a case of primary cutaneous diffuse large B-cell lymphoma (PCDLBCL). This phenomenon is of great significance as the subsequent prognosis becomes poor and the prophylactic central nervous system (CNS) therapy if administered, can reduce the chances of relapse, however, the survival benefit remains uncertain. The role of prophylactic CNS therapy is not well defined in the case of PCDLBCL. CASE: We report a case of PCDLBCL leg type with a low CNS International Prognostic Index (CNS-IPI) risk, who developed isolated leptomeningeal relapse in the form of bilateral facial nerve palsy. He was managed by 2nd line chemotherapy and CNS directed therapy and achieved complete remission. CONCLUSION: PCDLBCL leg type is an aggressive malignancy. Molecular/genomic mechanism likely responsible for CNS dissemination should be identified by prospective multi-centric studies that can better define the subsets of patients eligible for prophylactic therapy in the absence of a high CNS-IPI risk.
BACKGROUND: Isolated leptomeningeal relapse in a case of cutaneous lymphoma is an uncommon event more so in a case of primary cutaneous diffuse large B-cell lymphoma (PCDLBCL). This phenomenon is of great significance as the subsequent prognosis becomes poor and the prophylactic central nervous system (CNS) therapy if administered, can reduce the chances of relapse, however, the survival benefit remains uncertain. The role of prophylactic CNS therapy is not well defined in the case of PCDLBCL. CASE: We report a case of PCDLBCL leg type with a low CNS International Prognostic Index (CNS-IPI) risk, who developed isolated leptomeningeal relapse in the form of bilateral facial nerve palsy. He was managed by 2nd line chemotherapy and CNS directed therapy and achieved complete remission. CONCLUSION:PCDLBCL leg type is an aggressive malignancy. Molecular/genomic mechanism likely responsible for CNS dissemination should be identified by prospective multi-centric studies that can better define the subsets of patients eligible for prophylactic therapy in the absence of a high CNS-IPI risk.
Authors: E Gardette; A Maraval; F Brunet-Possenti; G Quereux; H Beltraminelli; I Templier; J Hodel; E Scherman; E Durot; M Bagot; A Pham-Ledard; F Grange; M Beylot-Barry; S Ingen-Housz-Oro Journal: J Eur Acad Dermatol Venereol Date: 2017-06-15 Impact factor: 6.166
Authors: Francisco-Javier Peñalver; Juan-Manuel Sancho; Adolfo de la Fuente; María-Teresa Olave; Alejandro Martín; Carlos Panizo; Elena Pérez; Antonio Salar; Alberto Orfao Journal: Haematologica Date: 2016-10-20 Impact factor: 9.941
Authors: Norbert Schmitz; Samira Zeynalova; Maike Nickelsen; Roopesh Kansara; Diego Villa; Laurie H Sehn; Bertram Glass; David W Scott; Randy D Gascoyne; Joseph M Connors; Marita Ziepert; Michael Pfreundschuh; Markus Loeffler; Kerry J Savage Journal: J Clin Oncol Date: 2016-07-05 Impact factor: 44.544
Authors: M Gleeson; N Counsell; D Cunningham; N Chadwick; A Lawrie; E A Hawkes; A McMillan; K M Ardeshna; A Jack; P Smith; P Mouncey; C Pocock; J A Radford; J Davies; D Turner; A Kruger; P Johnson; J Gambell; D Linch Journal: Ann Oncol Date: 2017-10-01 Impact factor: 32.976